CSIMarket
 


Caribou Biosciences Inc   (CRBU)
Other Ticker:  
 
 

CRBU's Revenue Growth by Quarter and Year

Caribou Biosciences Inc 's Revenue results by quarter and year




CRBU Revenue (in millions $) FY 2024 FY 2023 FY 2022 FY 2021
IV Quarter December - 3.56 3.69 -5.45
III Quarter September - 23.66 3.30 3.98
II Quarter June - 3.76 4.19 1.48
I Quarter March 2.43 3.50 2.66 0.00
FY   2.43 34.48 13.84 0.01



CRBU Revenue first quarter 2024 Y/Y Growth Comment
Caribou Biosciences Inc reported fall in Revenue in the first quarter 2024 by -30.6% to $ 2.43 millions, from the same quarter in 2023.
The drop in the first quarter 2024 Caribou Biosciences Inc 's Revenue compares unfavorably to the Company's average Revenue doubling of 305.62%.

Looking into first quarter 2024 results within Biotechnology & Pharmaceuticals industry 12 other companies have achieved higher Revenue growth. While Caribou Biosciences Inc ' s Revenue drop of -30.6% ranks overall at the positon no. 989 in the first quarter 2024.




CRBU Revenue ( Y/Y Growth %) 2024
2023 2022 2021
IV Quarter December - -3.52 % - -
III Quarter September - 616.97 % -17.09 % -
II Quarter June - -10.26 % 183.11 % -
I Quarter March -30.6 % 31.58 % - -
FY   - 149.13 % 138300 % -

Financial Statements
Caribou Biosciences Inc 's first quarter 2024 Revenue $ 2.43 millions CRBU's Income Statement
Caribou Biosciences Inc 's first quarter 2023 Revenue $ 3.50 millions Quarterly CRBU's Income Statement
New: More CRBU's historic Revenue Growth >>


CRBU Revenue (Quarter on Quarter Growth %)

2024
2023 2022 2021
IV Quarter December - -84.95 % 11.82 % -
III Quarter September - 529.26 % -21.24 % 168.92 %
II Quarter June - 7.43 % 57.52 % -
I Quarter March -31.77 % -5.15 % - -
FY (Year on Year)   - 149.13 % 138300 % -




Revenue first quarter 2024 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #13
Healthcare Sector #185
Overall #989

Revenue Y/Y Growth Statistics
High Average Low
635.47 % 305.62 % 127.41 %
(Sep 30 2023)   (Mar 31 2024)
Revenue first quarter 2024 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #13
Healthcare Sector #185
Overall #989
Revenue Y/Y Growth Statistics
High Average Low
635.47 % 305.62 % 127.41 %
(Sep 30 2023)   (Mar 31 2024)

Revenue by Quarter for the Fiscal Years 2021, 2022, 2023, 2024

Caribou Biosciences Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
530.15 % 70.32 % -84.96 %
(Sep 30 2023)  


CRBU's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2024 Caribou Biosciences Inc disclosed fall in Revenue sequentially by -31.77% to $ 2.43 millions, from $ 3.56 millions declared in the previous reporting period.

This is not huge problem, as Caribou Biosciences Inc 's Revenue always seem to slow in the I. Quarter Alejandro Green, an industry veteran told.

Within Biotechnology & Pharmaceuticals industry 24 other companies have achieved higher Revenue quarter on quarter growth. While Caribou Biosciences Inc 's Revenue growth quarter on quarter, overall rank is 2248.


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #25
Healthcare Sector #298
Overall #2248
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #25
Healthcare Sector #298
Overall #2248
Revenue Q/Q Growth Statistics
High Average Low
530.15 % 70.32 % -84.96 %
(Sep 30 2023)  


CRBU's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2024 Caribou Biosciences Inc reported fall in Revenue from the fourth quarter by -31.77% to $ 2.43 millions, from $ 3.56 millions achived in the previous quarter.

If you evaluate current shortcoming at the I. Quarter, you must presume, that usually I. Quarter 2024 results emerge softer in contrast to the quarter before

Within Biotechnology & Pharmaceuticals industry 24 other companies have achieved higher Revenue quarter on quarter growth. While Caribou Biosciences Inc 's Revenue growth quarter on quarter, overall rank is 2248.


Caribou Biosciences Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Mar 31 2024)
12 Months Ending
(Dec 31 2023)
12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
Cumulative Revenue 12 Months Ending $ 33.40 $ 34.48 $ 34.61 $ 14.25 $ 14.69
Y / Y Revenue Growth (TTM) 127.41 % 148.91 % 635.47 % 164.91 % 451.39 %
Year on Year Revenue Growth Overall Ranking # 9 # 13 # 14 # 26 # 20
Seqeuential Revenue Change (TTM) -3.11 % -0.39 % 142.85 % -2.98 % 6.05 %
Seq. Revenue Growth (TTM) Overall Ranking # 989 # 27 # 1579 # 271 # 280




Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Mar 31 2024 period, Caribou Biosciences Inc 's cumulative twelve months Revenue were $ 33 millions, company would post below average annual Revenue growth of 6.05% year on year, if the fiscal year would end at Mar 31 2024.
A slow-down in the Caribou Biosciences Inc 's Revenue growth from the 3.56% growth in Dec 31 2023.

Looking into Healthcare sector trailing twelve month Revenue increase, only one company had higher growth. While Total ranking has impoved so far to 9, from total ranking in previous quarter at 13.

Revenue TTM Q/Q Growth Statistics
High Average Low
635.47 %
305.62 %
127.41 %
 

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 13
Healthcare Sector # 2
Overall # 9

Revenue TTM Y/Y Growth Statistics
High Average Low
635.47 %
305.62 %
127.41 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 13
Sector # 185
S&P 500 # 989
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Mar 31 2024 period, Caribou Biosciences Inc 's cumulative twelve months Revenue were $ 33 millions, company would post below average annual Revenue growth of 127.41% year on year, if the fiscal year would end at Mar 31 2024.
A slow-down in the Caribou Biosciences Inc 's Revenue growth from the 3.56% growth in Dec 31 2023.

Looking into Healthcare sector trailing twelve month Revenue increase, only one company had higher growth. While Total ranking has impoved so far to 9, from total ranking in previous quarter at 13.

Revenue TTM Q/Q Growth Statistics
High Average Low
635.47 %
305.62 %
127.41 %
 


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 13
Healthcare Sector # 2
Overall # 9

Revenue TTM Y/Y Growth Statistics
High Average Low
635.47 %
305.62 %
127.41 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 13
Sector # 185
S&P 500 # 989




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
CRBU's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth
Revenue Growth for CRBU's Competitors
Revenue Growth for Caribou Biosciences Inc 's Suppliers
Revenue Growth for CRBU's Customers

You may also want to know
CRBU's Annual Growth Rates CRBU's Profitability Ratios CRBU's Asset Turnover Ratio CRBU's Dividend Growth
CRBU's Roe CRBU's Valuation Ratios CRBU's Financial Strength Ratios CRBU's Dividend Payout Ratio
CRBU's Roa CRBU's Inventory Turnover Ratio CRBU's Growth Rates CRBU's Dividend Comparisons



Companies with similar Revenue fall for the quarter ending Mar 31 2024 within Healthcare SectorY/Y Change %Revenue for the quarter ending Mar 31 2024
Collegium Pharmaceutical inc -0.21%$ -0.215 millions
Mettler Toledo International Inc-0.30%$ -0.300 millions
3m Company-0.35%$ -0.349 millions
Icu Medical Inc-0.42%$ -0.423 millions
Lifeloc Technologies Inc -0.51%$ -0.513 millions
Regeneron Pharmaceuticals Inc -0.54%$ -0.541 millions
Envista Holdings Corporation-0.62%$ -0.622 millions
Vyne Therapeutics Inc -1.01%$ -1.010 millions
Ge Healthcare Technologies Inc -1.50%$ -1.502 millions
Baxter International Inc -1.56%$ -1.562 millions
Y mabs Therapeutics inc -1.58%$ -1.580 millions
Pacific Biosciences Of California Inc -1.59%$ -1.589 millions
Cartesian Therapeutics Inc -1.65%$ -1.650 millions
Viatris Inc -1.76%$ -1.762 millions
Ocuphire Pharma Inc -2.17%$ -2.173 millions
Vaso Corporation-2.51%$ -2.513 millions
Dentsply Sirona Inc -2.56%$ -2.556 millions
Alpha Pro Tech Ltd -2.78%$ -2.775 millions
Prestige Consumer Healthcare Inc -2.82%$ -2.817 millions
West Pharmaceutical Services Inc -2.99%$ -2.986 millions
Integra Lifesciences Holdings Corp-3.14%$ -3.144 millions
Accelerate Diagnostics Inc -3.17%$ -3.165 millions
National Research Corporation-3.18%$ -3.180 millions
Catheter Precision Inc -3.53%$ -3.529 millions
Elanco Animal Health Inc-4.14%$ -4.137 millions
Ptc Therapeutics inc -4.66%$ -4.657 millions
Foghorn Therapeutics Inc -4.88%$ -4.879 millions
Aclaris Therapeutics Inc -5.14%$ -5.142 millions
Avantor Inc -5.65%$ -5.645 millions
The Beauty Health Company-5.70%$ -5.699 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com